Connor Iapoce

Data show cfPWV at 17.7 years was independently and directly associated with total fat mass and trunk fat mass at 24.5 years.

Patients with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis and significantly improved insulin sensitivity versus conventional therapy.

Data show the age-adjusted prevalence of hyperinsulinemia in adults without diabetes increased by 18% in the study population between 1999 - 2000 and 2017 - 2018.

Data show the HR of the risk between T2D and T2D rates of developing complications were 1.88 (95% CI, 1.13 - 3.12; P = .02) for any diabetic retinopathy.

Data show the absolute risk difference for the development of PPHN after exposure to antidepressants in late pregnancy was 1.3 per 1000 infants.

The approval of daratumumab and hyaluronidase-fihj plus carfilzomib and dexamethasone is for treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.

A NDM cohort in Israel found those with TNDM were taller and heavier compared to PNDM, while chronic diabetes complications developed in patients with long-standing NDM.

The ergonomic device for the treatment of diabetes is the only insulin patch pump for closed loop integration able to be used with standard, pre-filled pump cartridges.

VX-880 stem cell-derived therapy demonstrated restoration of insulin production and was generally well-tolerated in T1D treatment.

Data show the multivariable-adjusted HR for increase in seafood consumption of 1 oz per day and all-cause mortality was 0.84 and for CVD-related mortality was 0.89.

Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.

Patients considered adherent to caFFR had a significantly lower risk of MACE, compared to non-adherent patients (adjusted hazard ratio, 0.33).

In models adjusting for age, sex, and race/ethnicity, children with a parent with type 2 diabetes reported higher symptoms of anxiety and depression.

Data show hemoglobin level of SGLT2 inhibitor users were higher at an eGFR above >15 mL/min/1.73m2 compared to non-users.

The overall risk of SARS-CoV-2 breakthrough infection was 15.4% in the multiple myeloma population and 3.9% in the noncancer population.

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.

Adults aged 18–29 years (87%) with diabetes were more likely to report missed medical care during COVID-19, compared to those aged 30–59 years (63%) or ≥60 years (26%).

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

Investigators noted that several types of AID systems improved Time-in-Range and HbA1c with minimal concerns around severe hypoglycemia in type 1 diabetes care.

Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.

At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.

The agent is the first therapeutic treatment indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.

Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results

Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.

Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.

Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.

Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.

Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.

Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.